publication venue for
- The justification for the progressive fibrotic phenotype. 27:363-367. 2021
- Allergen bronchoprovocation test: an important research tool supporting precision medicine. 27:15-22. 2021
- Progressive fibrosing interstitial lung disease: treatable traits and therapeutic strategies. 26:436-442. 2020
- Pulmonary rehabilitation in interstitial lung diseases. 26:470-476. 2020
- Systemic sclerosis-associated interstitial lung disease. 26:487-495. 2020
- Anti-alarmin approaches entering clinical trials. 26:69-76. 2020
- Cystic fibrosis survival. 24:574-578. 2018
- Antialarmins for treatment of asthma. 24:32-41. 2018
- Glucocortiosteroid subsensitivity and asthma severity. 23:78-88. 2017
- Therapeutic implications of ‘neutrophilic asthma’. 21:33-38. 2015
- Monoclonal antibodies for the treatment of refractory asthma. 20:87-94. 2014
- Extracellular matrix microenvironment contributes actively to pulmonary fibrosis. 19:446-452. 2013
- The cystic fibrosis airway microbiome. 18:622-627. 2012
- Treatment of venous thromboembolism with dabigatran. 18:410-415. 2012
- Bronchial thermoplasty for severe asthma. 17:34-38. 2011
- Early interventions with inhaled corticosteroids in asthma: benefits and risks. 17:12-15. 2011
- The addition of long-acting beta-agonists to inhaled corticosteroids in asthma. 17:23-28. 2011
- Bleeding and venous thromboembolism in the critically ill with emphasis on patients with renal insufficiency. 15:455-462. 2009
- Prevention of venous thromboembolism in hospitalized medical patients: addressing some practical questions. 14:381-388. 2008
- New interventions in asthma including bronchial thermoplasty. 14:77-81. 2008
- Low molecular weight heparin and bleeding in patients with chronic renal failure. 13:409-413. 2007
- Perioperative bridging interruption with heparin for the patient receiving long-term anticoagulation. 4:602-608. 2005
- Anticoagulation therapy in the antiphospholipid syndrome: recent advances. 11:368-372. 2005
- The impact of patient compliance on effective asthma management. 9:S8-S10. 2003
- Current agents for the treatment of patients with heparin-induced thrombocytopenia. 8:405-412. 2002
- Current agents for the treatment of patients with heparin-induced thrombocytopenia. 8:405-412. 2002
- Factor Xa inhibition in the prevention of venous thromboembolism and treatment of patients with venous thromboembolism. 8:398-404. 2002
- Factor Xa inhibition in the prevention of venous thromboembolism and treatment of patients with venous thromboembolism. 8:398-404. 2002
- Prognosis in pulmonary embolism. 7:354-359. 2001
- Duration of anticoagulants in acute or recurrent venous thromboembolism. 6:321-325. 2000
- Venous thromboembolism in heparin-induced thrombocytopenia. 6:343-351. 2000
- Health-related quality of life in asthma. 5:105-105. 1999
- Changing delivery methods for obstructive lung diseases. 3:177-189. 1997
- Antimicrobial approaches to therapy for pneumonia. 2:218-227. 1996
- Diagnosis of chronic obstructive pulmonary disease and differentiation from asthma. 2:148-154. 1996